Radiopharmaceuticals Market Companies, Size & Trends 2026-2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Radiopharmaceuticals Market

5.1. COVID-19 Landscape: Radiopharmaceuticals Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Radiopharmaceuticals Market, By Radioisotope

8.1. Radiopharmaceuticals Market, by Radioisotope

8.1.1. Iodine I

8.1.1.1. Market Revenue and Forecast

8.1.2. Gallium 68

8.1.2.1. Market Revenue and Forecast

8.1.3. Technetium 99m

8.1.3.1. Market Revenue and Forecast

8.1.4. Fluorine 18

8.1.4.1. Market Revenue and Forecast

8.1.5. Others

8.1.5.1. Market Revenue and Forecast

Chapter 9. Global Radiopharmaceuticals Market, By Application

9.1. Radiopharmaceuticals Market, by Application

9.1.1. Cancer

9.1.1.1. Market Revenue and Forecast

9.1.2. Cardiology

9.1.2.1. Market Revenue and Forecast

9.1.3. Others

9.1.3.1. Market Revenue and Forecast

Chapter 10. Global Radiopharmaceuticals Market, By Type

10.1. Radiopharmaceuticals Market, by Type

10.1.1. Diagnostic

10.1.1.1. Market Revenue and Forecast

10.1.2. Therapeutic

10.1.2.1. Market Revenue and Forecast

Chapter 11. Global Radiopharmaceuticals Market, By End User

11.1. Radiopharmaceuticals Market, by End User

11.1.1. Hospitals and clinics

11.1.1.1. Market Revenue and Forecast

11.1.2. Medical Imaging centers

11.1.2.1. Market Revenue and Forecast

11.1.3. Others

11.1.3.1. Market Revenue and Forecast

Chapter 12. Global Radiopharmaceuticals Market, Regional Estimates, and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Radioisotope

12.1.2. Market Revenue and Forecast, by Application

12.1.3. Market Revenue and Forecast, by Type

12.1.4. Market Revenue and Forecast, by End User

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Radioisotope

12.1.5.2. Market Revenue and Forecast, by Application

12.1.5.3. Market Revenue and Forecast, by Type

12.1.5.4. Market Revenue and Forecast, by End User

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Radioisotope

12.1.6.2. Market Revenue and Forecast, by Application

12.1.6.3. Market Revenue and Forecast, by Type

12.1.6.4. Market Revenue and Forecast, by End User

12.2. Europe

12.2.1. Market Revenue and Forecast, by Radioisotope

12.2.2. Market Revenue and Forecast, by Application

12.2.3. Market Revenue and Forecast, by Type

12.2.4. Market Revenue and Forecast, by End User

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Radioisotope

12.2.5.2. Market Revenue and Forecast, by Application

12.2.5.3. Market Revenue and Forecast, by Type

12.2.5.4. Market Revenue and Forecast, by End User

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Radioisotope

12.2.6.2. Market Revenue and Forecast, by Application

12.2.6.3. Market Revenue and Forecast, by Type

12.2.6.4. Market Revenue and Forecast, by End User

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Radioisotope

12.2.7.2. Market Revenue and Forecast, by Application

12.2.7.3. Market Revenue and Forecast, by Type

12.2.7.4. Market Revenue and Forecast, by End User

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Radioisotope

12.2.8.2. Market Revenue and Forecast, by Application

12.2.8.3. Market Revenue and Forecast, by Type

12.2.8.4. Market Revenue and Forecast, by End User

12.3. APAC

12.3.1. Market Revenue and Forecast, by Radioisotope

12.3.2. Market Revenue and Forecast, by Application

12.3.3. Market Revenue and Forecast, by Type

12.3.4. Market Revenue and Forecast, by End User

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Radioisotope

12.3.5.2. Market Revenue and Forecast, by Application

12.3.5.3. Market Revenue and Forecast, by Type

12.3.5.4. Market Revenue and Forecast, by End User

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Radioisotope

12.3.6.2. Market Revenue and Forecast, by Application

12.3.6.3. Market Revenue and Forecast, by Type

12.3.6.4. Market Revenue and Forecast, by End User

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Radioisotope

12.3.7.2. Market Revenue and Forecast, by Application

12.3.7.3. Market Revenue and Forecast, by Type

12.3.7.4. Market Revenue and Forecast, by End User

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Radioisotope

12.3.8.2. Market Revenue and Forecast, by Application

12.3.8.3. Market Revenue and Forecast, by Type

12.3.8.4. Market Revenue and Forecast, by End User

12.4. MEA

12.4.1. Market Revenue and Forecast, by Radioisotope

12.4.2. Market Revenue and Forecast, by Application

12.4.3. Market Revenue and Forecast, by Type

12.4.4. Market Revenue and Forecast, by End User

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Radioisotope

12.4.5.2. Market Revenue and Forecast, by Application

12.4.5.3. Market Revenue and Forecast, by Type

12.4.5.4. Market Revenue and Forecast, by End User

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Radioisotope

12.4.6.2. Market Revenue and Forecast, by Application

12.4.6.3. Market Revenue and Forecast, by Type

12.4.6.4. Market Revenue and Forecast, by End User

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Radioisotope

12.4.7.2. Market Revenue and Forecast, by Application

12.4.7.3. Market Revenue and Forecast, by Type

12.4.7.4. Market Revenue and Forecast, by End User

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Radioisotope

12.4.8.2. Market Revenue and Forecast, by Application

12.4.8.3. Market Revenue and Forecast, by Type

12.4.8.4. Market Revenue and Forecast, by End User

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Radioisotope

12.5.2. Market Revenue and Forecast, by Application

12.5.3. Market Revenue and Forecast, by Type

12.5.4. Market Revenue and Forecast, by End User

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Radioisotope

12.5.5.2. Market Revenue and Forecast, by Application

12.5.5.3. Market Revenue and Forecast, by Type

12.5.5.4. Market Revenue and Forecast, by End User

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Radioisotope

12.5.6.2. Market Revenue and Forecast, by Application

12.5.6.3. Market Revenue and Forecast, by Type

12.5.6.4. Market Revenue and Forecast, by End User

Chapter 13. Company Profiles

13.1. Bayer AG

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Iso-Tex Diagnostics, Inc

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Jubilant Pharmova Limited

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Novartis AG

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. General Electric Company

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Lantheus Holdings, Inc

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Eli Lilly and Company

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Siemens AG

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Curium Pharma

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Cardinal Health Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The market is estimated at USD 9.0 billion in 2025 and USD 21.5 billion by 2030 in the base case, a CAGR of about 19%. Therapeutics grow from USD 3.6 billion to about USD 12 billion, contributing roughly USD 8.5 billion, or about 70% of the increment. Diagnostics grow at about 11% CAGR and add the remainder.

Answer : Lu-177 accounts for about 85% of therapeutic revenue today, roughly USD 3 billion. Earlier-line expansion is the main upside lever, so Lu-177 should remain the largest therapeutic pool through 2030 even as its share dilutes. Analyst view: isotope supply and treatment-site capacity, rather than demand, will determine how much of the upside is captured.

Answer : Alpha emitters (Ac-225, Pb-212) are the fastest-growing isotope group but start from a small base, and no validated share figure is available yet. Analyst view: they will remain a minority of therapeutic value in 2030 while growing faster than any other pool, with the multi-billion-dollar opportunity depending on commercial-scale isotope supply.

Answer : Legacy diagnostics cost tens to a few hundred USD per dose, novel PET tracers about USD 2,000-4,000, and Lu-177 therapy USD 40,000-48,000 per dose (USD 190,000-260,000 per course in the US). European and Asian prices are 30-50% below US levels. Analyst view: the spread reflects IP protection, clinical differentiation and reimbursement more than production cost.

Answer : The research has no country ranking, and one would need facility-level data. Analyst view: the strongest candidates are import-dependent markets with active isotope-independence programs and existing nuclear or accelerator infrastructure, such as the US, EU members, Japan and India. Announced production projects already represent well over USD 1 billion of investment.